Key result
Gene and protein therapies represent prospective approaches for treating the underlying causes of channelopathies, whereas current treatment options remain largely symptomatic.
Why the study?
Current treatments for most channelopathies remain symptomatic, and therapies that rectify the underlying cause by delivering or expressing functional ion channels are lacking.
Gene and protein therapies represent promising future strategies to treat the root causes of channelopathies, moving beyond current purely symptomatic management.
Answers are grounded in this paper and cite their sources.
Gene and protein therapies for channelopathies require clinical validation; leaves open their role beyond symptomatic care.
Reduced cell surface expression or the malfunctioning of ion channels gives rise to a group of disorders known as channelopathies. To treat the underlying cause, the delivery and/or expression of a functional ion channel into the cell membrane of the cell of interest is required. Unfortunately, for most channelopathies, current treatment options are only symptomatic and treatments that rectify the underlying damage are still lacking. Within this context, approaches that rely on gene and protein therapy are required. Gene therapy would allow the expression of a functional protein, provided that the cellular machinery in the diseased cell could correctly fold and traffic the protein to the cell membrane. Whereas protein therapy would allow the direct delivery of a functional protein, provided that the purification process does not affect protein function and a suitable delivery vehicle for targeted delivery is used. In this review, we provide an overview of channelopathies and available symptomatic treatments. The current state of gene therapy approaches mainly using viral vectors is discussed, which is followed by the role of nanomedicine in protein therapy and how nanomedicine could be exploited for the delivery of functional ion channels to diseased cells.
No takes yet. Share an insight, caveat, or question.
Sakla et al. (2023) conducted a review in Channelopathies. Gene and protein therapy was evaluated. Gene and protein therapies represent prospective approaches for treating the underlying causes of channelopathies, whereas current treatment options remain largely symptomatic.
Synapse has enriched 10 related papers. Consider them for comparative context: